{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T21:06:52Z","timestamp":1792098412029,"version":"4.4.0"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,8]]},"DOI":"10.1097\/rlu.0000000000000481","type":"journal-article","created":{"date-parts":[[2014,7,2]],"date-time":"2014-07-02T04:17:21Z","timestamp":1404274641000},"page":"685-689","source":"Crossref","is-referenced-by-count":42,"title":["Correlation Between PET\/CT Parameters and KRAS Expression in Colorectal Cancer"],"prefix":"10.1097","volume":"39","author":[{"given":"Shang-Wen","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua-Che","family":"Chiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William Tzu-Liang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Te-Chun","family":"Hsieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuo-Yang","family":"Yen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-Fen","family":"Chiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Hung","family":"Kao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-3-20210204","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3322\/caac.20107","article-title":"Global cancer statistics.","volume":"61","author":"Jemal","year":"2011","journal-title":"Ca Cancer J Clin"},{"key":"R2-3-20210204","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1056\/NEJMoa071834","article-title":"Cetuximab for the treatment of colorectal cancer.","volume":"357","author":"Jonker","year":"2007","journal-title":"N Engl J Med"},{"key":"R3-3-20210204","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1056\/NEJMoa0804385","article-title":"KRAS mutations and benefit from cetuximab in advanced colorectal cancers.","volume":"359","author":"Karapetis","year":"2008","journal-title":"N Engl J Med"},{"key":"R4-3-20210204","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1200\/JCO.2007.12.5906","article-title":"KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.","volume":"26","author":"Lievre","year":"2008","journal-title":"J Clin Oncol"},{"key":"R5-3-20210204","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1200\/JCO.2007.14.7116","article-title":"Wild-type KRAS is required for panitumumab efficiency in patients with metastatic colorectal cancer.","volume":"26","author":"Amado","year":"2008","journal-title":"J Clin Oncol"},{"key":"R6-3-20210204","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1158\/1078-0432.CCR-11-1909","article-title":"Relationship between 18F-fluorodeoxyglucose accumulation and KRASBRAF mutations in colorectal cancer.","volume":"18","author":"Kawada","year":"2012","journal-title":"Clin Cancer Res"},{"key":"R7-3-20210204","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1056\/NEJMra0804588","article-title":"Molecular origins of cancer: molecular basis of colorectal cancer.","volume":"361","author":"Markowitz","year":"2009","journal-title":"N Engl J Med"},{"key":"R8-3-20210204","doi-asserted-by":"crossref","first-page":"7303","DOI":"10.1158\/1078-0432.CCR-11-1570","article-title":"Gene expression differences between colon and rectum tumors.","volume":"17","author":"Sanz-Pamplona","year":"2011","journal-title":"Clin Cancer Res"},{"key":"R9-3-20210204","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1007\/s00259-012-2127-7","article-title":"Use of pretreatment metabolic tumor volumes to predict the outcome of pharyngeal cancer treated by definitive radiotherapy.","volume":"39","author":"Kao","year":"2012","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R10-3-20210204","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/327298a0","article-title":"Detection of high incidence of K-ras oncogenes during human colon tumorigenesis.","volume":"327","author":"Forrester","year":"1987","journal-title":"Nature"},{"key":"R11-3-20210204","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S1095-0397(99)00016-3","article-title":"Tumor treatment response based on visual and quantitative changes in global tumor glycolysis using PET-FDG imaging: the visual response score and the change in total lesion glycolysis.","volume":"2","author":"Larson","year":"1999","journal-title":"Clin Positron Imaging"},{"key":"R12-3-20210204","first-page":"405","article-title":"Which FDGPET parameters of the primary tumors in colon or sigmoid cancer provide the best correlation with the pathological findings Eur J Radiol.","volume":"82","author":"Chen","year":"2013","journal-title":""},{"key":"R13-3-20210204","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJMoa0805019","article-title":"Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.","volume":"360","author":"van Cutsem","year":"2009","journal-title":"N Engl J Med"},{"key":"R14-3-20210204","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/S1470-2045(08)70206-7","article-title":"Assessment of somatic KRAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer.","volume":"9","author":"Linardou","year":"2008","journal-title":"Lancet Oncol"},{"key":"R15-3-20210204","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1200\/JCO.2009.21.9170","article-title":"American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy.","volume":"27","author":"Allegra","year":"2009","journal-title":"J Clin Oncol"},{"key":"R16-3-20210204","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.radonc.2010.07.019","article-title":"Clinical evidence on PET-CT for radiation therapy planning in gastro-intestinal tumors.","volume":"96","author":"Lambrecht","year":"2010","journal-title":"Radiother Oncol"},{"key":"R17-3-20210204","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1177\/153303460700600105","article-title":"Impact of integrated PETCT on variability of target volume delineation in rectal cancer.","volume":"6","author":"Patel","year":"2007","journal-title":"Technol Cancer Res Treat"},{"key":"R18-3-20210204","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.radonc.2010.07.003","article-title":"Segmentation of positron emission tomography images: some recommendations for target delineation in radiation oncology.","volume":"96","author":"Lee","year":"2010","journal-title":"Radiother Oncol"},{"key":"R19-3-20210204","first-page":"884","article-title":"F-18 FDG PETCT in rectal carcinoma: where are we now Clin Nucl Med.","volume":"36","author":"Grassetto","year":"2011","journal-title":""},{"key":"R20-3-20210204","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S0969-8051(97)00226-6","article-title":"FDG accumulation and tumor biology.","volume":"25","author":"Pauwels","year":"1998","journal-title":"Nucl Med Biol"},{"key":"R21-3-20210204","doi-asserted-by":"crossref","first-page":"24S","DOI":"10.2967\/jnumed.107.047258","article-title":"Causes and consequences of increased glucose metabolism of cancers.","volume":"49","author":"Gillies","year":"2008","journal-title":"J Nucl Med"},{"key":"R22-3-20210204","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.2967\/jnumed.108.054098","article-title":"18F-FDG uptake in lung, breast, and colon cancers: molecular biology correlates and disease characterization.","volume":"50","author":"Jadvar","year":"2009","journal-title":"J Nucl Med"},{"key":"R23-3-20210204","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1631\/jzus.B0820273","article-title":"Colorectal cancer, one entity or three.","volume":"10","author":"Li","year":"2009","journal-title":"J Zhejiang Univ Sci B"},{"key":"R24-3-20210204","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1158\/1078-0432.CCR-09-2446","article-title":"Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases.","volume":"16","author":"Baldus","year":"2010","journal-title":"Clin Cancer Res"},{"key":"R25-3-20210204","doi-asserted-by":"crossref","first-page":"932","DOI":"10.2967\/jnumed.106.035774","article-title":"Partial-volume effect in PET tumor imaging.","volume":"48","author":"Soret","year":"2007","journal-title":"J Nucl Med"},{"key":"R26-3-20210204","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/RLU.0000000000000265","article-title":"Biological target volume overlapping segmentation system method for avoiding false-positive PET findings in assessing response to neoadjuvant chemoradiation therapy in rectal cancer.","volume":"39","author":"Maffione","year":"2014","journal-title":"Clin Nucl Med"},{"key":"R27-3-20210204","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1158\/1078-0432.CCR-10-2542","article-title":"Overexpression of HMGA2 promotes metastasis and impacts survival of colorectal cancers.","volume":"17","author":"Wang","year":"2011","journal-title":"Clin Cancer Res"},{"key":"R28-3-20210204","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1007\/s00259-013-2357-3","article-title":"Fifteen different 18F-FDG PETCT qualitative and quantitative parameters investigated as pathological response predictors of locally advanced rectal cancer treated by neoadjuvant chemoradiation therapy.","volume":"40","author":"Maffione","year":"2013","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R29-3-20210204","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1097\/RLU.0b013e3182a20153","article-title":"Proposal of a new 18F-FDG PETCT predictor of response in rectal cancer treated by neoadjuvant chemoradiation therapy and comparison with PERCIST criteria.","volume":"38","author":"Maffione","year":"2013","journal-title":"Clin Nucl Med"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000000481","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T02:09:04Z","timestamp":1620958144000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00003072-201408000-00003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8]]},"references-count":29,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000000481","relation":{},"ISSN":["0363-9762"],"issn-type":[{"value":"0363-9762","type":"print"}],"subject":[],"published":{"date-parts":[[2014,8]]}}}